Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2021-02-10 Report Publication Anno…
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT annonce son calendrier financier pour 2021
Report Publication Announcement Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and its primary content is an announcement detailing the company's planned financial reporting dates for 2021, including the release of annual results, interim results, and the date of the Annual General Meeting (AGM). It explicitly states the schedule for publishing the 'Document d'Enregistrement Universel 2020' and the 'Rapport Financier Annuel' (Annual Financial Report) in April 2021. Since this document is an announcement *about* future reports and schedules, rather than the reports themselves, it fits the definition of a Report Publication Announcement (RPA). It is not the full 10-K/AR, nor is it a general regulatory filing (RNS) given the specific nature of announcing a schedule. The document length (7356 chars) is substantial, but the content is purely an announcement of dates, not the detailed financial data or narrative of the reports themselves.
2021-02-10 French
GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology
Regulatory Filings Classification · 95% confidence The document is explicitly titled and formatted as a "PRESS RELEASE". The content announces the publication of positive clinical trial results in a specific journal (*Journal of Hepatology*) and provides commentary from management and external experts. This type of announcement, which communicates key operational or scientific updates outside of mandatory periodic financial filings (like 10-K or IR), typically falls under an Earnings Release (ER) if it relates to performance, or more generally, a Regulatory Filing (RNS) if it's a broad announcement. However, since it is a press release announcing a scientific/clinical milestone (publication of results) rather than quarterly financial performance highlights (ER), and it is not a formal regulatory document like a 10-K or a specific notice like DIV or DIRS, the most appropriate category is the general regulatory announcement fallback, RNS, or potentially ER if the context implies it's tied to a reporting cycle. Given the focus is purely on the publication of clinical data, which is a significant corporate event announcement, RNS (Regulatory Filings/General Announcement) is the best fit, as ER usually focuses on financial metrics. It is not short enough to be a simple RPA, as it contains substantial detail and commentary.
2021-02-09 English
GENFIT : publication des résultats positifs de l’essai clinique de Phase 2 évaluant elafibranor chez des patients atteints de PBC dans le Journal of Hepatology
Regulatory Filings Classification · 90% confidence The document is a press release from GENFIT dated February 9, 2021, announcing the publication of positive Phase 2 clinical trial results for their drug elafibranor in the *Journal of Hepatology*. It discusses clinical trial progress (Phase 2 results, Phase 3 ELATIVE trial initiation, expected results in Q1 2023), regulatory designations (Breakthrough Therapy, Orphan Drug), and includes standard forward-looking statements and contact information typical of corporate news releases. This content is a direct announcement of scientific/clinical progress and results, not a formal regulatory filing like a 10-K, a quarterly report (IR), or a transcript (CT). It is a high-level summary of results and future plans aimed at investors and the public. This fits best under the category of an Earnings Release (ER) if it were tied to a financial period, but since it is specifically about clinical trial results and publication, it is more aligned with a general corporate update. Given the options, it is a press release announcing significant operational/scientific news. While it contains financial context (company updates), it is primarily a scientific/clinical update. However, in the context of standard SEC/financial filings, press releases announcing key operational milestones often fall under general news or, if they contain key performance indicators, sometimes resemble an Earnings Release (ER) structure, even if the core topic is clinical. Since it is a formal announcement of results and progress, and not a request for a vote (DEF 14A/PSI) or a management change (MANG), the closest fit among the provided codes for a major, non-financial-period-specific corporate announcement detailing progress is often the Earnings Release (ER) category, which frequently encompasses major operational updates, or potentially Regulatory Filings (RNS) as a fallback. Given the focus on trial results and future outlook, it functions similarly to an ER announcing operational milestones rather than just financial figures. However, since it is a press release announcing the publication of scientific data, and not explicitly an 'Earnings Release' (which usually focuses on revenue/profit), the most appropriate general category for a significant, non-standard announcement is often RNS, or if we interpret 'ER' broadly as 'Key Announcement Release', it could fit there. Given the strong focus on clinical data and regulatory milestones, and the lack of a specific 'Clinical Update' code, I will classify it as a general Regulatory Filing (RNS) as it is a formal announcement to the market about a significant event, or ER if we consider it a major operational update release. Since it is a press release announcing a publication, and not a formal regulatory document like a 10-K, RNS is a safer general classification for non-standard announcements. Let's re-evaluate: It is a press release announcing positive clinical data publication. This is a common type of corporate communication. It is not a 10-K, AR, IR, CT, or DEF 14A. It is not a DIV or NAV. It is not a MANG or DIRS. It is a major corporate announcement. If we must choose from the list, RNS (Regulatory Filings/Miscellaneous) is the best fit for a press release that doesn't fit the specific financial/governance categories, although it shares characteristics with an ER (announcing key performance/progress). I will lean towards RNS as the most encompassing category for non-standard, material press releases.
2021-02-09 French
GENFIT annonce la nomination de deux nouveaux membres au Comité Exécutif de la Société
Board/Management Information Classification · 100% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces significant changes in senior management: the appointment of Pascal Caisey as Chief Commercial Officer and Philippe Motté as Chief Regulatory and Quality Officer to the Executive Committee. This directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in senior management. Although it is a press release, the core content is the management change, not the announcement of a report (RPA) or a general regulatory filing (RNS). The length (8965 chars) is substantial enough to contain the full announcement details.
2021-01-28 French
GENFIT Announces Two Key Appointments to the Executive Committee
Board/Management Information Classification · 100% confidence The document is explicitly titled 'PRESS RELEASE' and announces the appointment of two individuals, Pascal Caisey and Philippe Motté, to the Executive Committee. This action directly relates to changes in the company's senior management team. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The content is a clear announcement of management changes, not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A).
2021-01-28 English
GENFIT : Corrections techniques sur les votes de l’Assemblée des Porteurs du 25 janvier 2021 sans conséquences sur l’approbation des résolutions
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a press release from GENFIT dated January 27, 2021, announcing 'Corrections techniques sur les votes de l'Assemblée des Porteurs' (Technical corrections on the votes of the Shareholders' Meeting) held on January 25, 2021. This document explicitly details the revised voting results for specific resolutions (Résolution n°1, n°2, n°3) from a general meeting of bondholders ('Assemblée des Porteurs'). This content directly relates to the official results from a shareholder vote, which aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not the full AGM presentation (AGM-R), nor is it a general earnings release (ER) or a comprehensive quarterly report (IR).
2021-01-27 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.